Amit Munshi
Chairman bij ZURA BIO LIMITED
Vermogen: 2 M $ op 29-02-2024
Profiel
Founder of Johnson & Johnson, Kythera Biopharmaceuticals LLC, Nephrian, Inc. and Oxeia Biopharmaceuticals, Inc., Amit Dilip Munshi is an entrepreneur and businessperson who has been at the head of 11 different companies and presently is Co-Chairman at Enterprise Therapeutics Ltd., Chairman of Zura Bio Ltd.
and Chief Executive Officer & Director at ReNAgade Therapeutics, Inc. Mr. Munshi is also on the board of Pulmatrix Operating Co., Inc., Adrista, Inc., Onebiopharma, Inc. and Galecto, Inc. (former Chairman).
In his past career he held the position of Director at Cytrellis Biosystems, Inc., President & Chief Executive Officer at Percivia LLC, President, Chief Executive Officer & Director at EPIRUS Biopharmaceuticals, Inc. President, Chief Executive Officer & Director at Zalicus, Inc. and Chief Executive Officer for EPIRUS Biopharmaceuticals, Inc. (both are subsidiaries of EPIRUS Biopharmaceuticals, Inc.), General Manager-Nephrology Europe at Amgen, Inc., Chief Business Officer for Johnson & Johnson and Principal at Iolab Corp.
(a subsidiary of Johnson & Johnson), President, Chief Executive Officer & Director at Arena Pharmaceuticals, Inc., Chairman-Management Board at Arena Pharmaceuticals GmbH, Chief Business Officer at Kythera Biopharmaceuticals LLC, Principal at Astra Merck, Inc., Director at Oxeia Biopharmaceuticals, Inc. and Director at Nephrian, Inc.
Mr. Munshi received an undergraduate degree from the University of California, Riverside and an MBA from Peter F Drucker & Masatoshi Ito Graduate School of Management.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ZURA BIO LIMITED CLASS A
1.42% | 05-06-2023 | 617 640 ( 1.42% ) | 2 M $ | 29-02-2024 |
GALECTO, INC.
0.02% | 14-06-2023 | 4 793 ( 0.02% ) | 3 451 $ | 29-02-2024 |
Actieve functies van Amit Munshi
Bedrijven | Functie | Begin |
---|---|---|
GALECTO, INC. | Director/Board Member | - |
ZURA BIO LIMITED | Chairman | - |
Adrista, Inc. | Director/Board Member | - |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Director/Board Member | - |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Director/Board Member | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Chairman | 01-01-2020 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Chief Executive Officer | - |
Eerdere bekende functies van Amit Munshi
Bedrijven | Functie | Einde |
---|---|---|
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. IV | Director/Board Member | 04-08-2022 |
Arena Pharmaceuticals GmbH
Arena Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals GmbH engages in the invention, development, production, and marketing of pharmaceutical products. The company was founded on May 18, 2007 and is headquartered in Zofingen, Switzerland. | Chief Executive Officer | 15-03-2022 |
░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Amit Munshi
University of California, Riverside | Undergraduate Degree |
Peter F Drucker & Masatoshi Ito Graduate School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 6 |
---|---|
AMGEN INC. | Health Technology |
JOHNSON & JOHNSON | Health Technology |
LUNGLIFE AI, INC. | Health Services |
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
PULMATRIX, INC. | Health Technology |
ZURA BIO LIMITED | Health Technology |
Bedrijven in privébezit | 18 |
---|---|
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Health Technology |
Kythera Biopharmaceuticals LLC
Kythera Biopharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA. | Health Technology |
Cytrellis Biosystems, Inc.
Cytrellis Biosystems, Inc. Medical SpecialtiesHealth Technology Cytrellis Biosystems, Inc. designs and develops aesthetic devices. The company was founded by William Gerald Austen and Doug A. Levinson and is headquartered in Boston, MA. | Health Technology |
Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Health Technology |
Astra Merck, Inc.
Astra Merck, Inc. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Astra Merck, Inc. is a private company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million. | Health Technology |
Percivia LLC
Percivia LLC Miscellaneous Commercial ServicesCommercial Services Percivia LLC engages in the research and development of vaccine and recombinant protein products. The company was founded in 2006 and is headquartered in Cambridge, MA. | Commercial Services |
Iolab Corp. | |
EPIRUS Biopharmaceuticals, Inc. /Old/
EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | Health Technology |
Nephrian, Inc. | |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Health Technology |
Adrista, Inc. | |
Arena Pharmaceuticals GmbH
Arena Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals GmbH engages in the invention, development, production, and marketing of pharmaceutical products. The company was founded on May 18, 2007 and is headquartered in Zofingen, Switzerland. | Health Technology |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Services |
Galecto, Inc. | |
Social Capital Suvretta Holdings Corp. IV
Social Capital Suvretta Holdings Corp. IV Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. IV operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Chamath Palihapitiya and Kishen C. Mehta on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Health Technology |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |